NVCR
Novocure Ltd
$16.31
-0.72
(-4.23%)
Mkt Cap
1.89B
Volume
1,360,330
52W Range
9.82-21.451
Sector
Healthcare
Beta
0.94
EPS (TTM)
-1.30
P/E Ratio
-10.60
Revenue (TTM)
699.19M
Rev Growth (5Y)
+5.8%
EPS Growth (5Y)
N/A
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 655.35M | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M | 351.32M | 248.07M | 177.03M | 82.89M | 33.09M | 15.49M |
| Net Income | (136.23M) | (168.63M) | (207.04M) | (92.53M) | (58.35M) | 19.81M | (7.23M) | (63.56M) | (61.66M) | (131.84M) | (111.58M) | (80.68M) |
| EPS | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | -0.70 | -1.54 | -1.34 | -1.12 |
| Free Cash Flow | (75.68M) | (69.22M) | (100.43M) | 9.43M | 58.59M | 84.18M | 16.14M | (8.58M) | (40.50M) | (125.26M) | (110.16M) | (76.56M) |
| FCF / Share | -0.68 | -0.64 | -0.94 | 0.09 | 0.57 | 0.83 | 0.17 | -0.09 | -0.46 | -1.46 | -1.32 | -1.06 |
| Operating CF | (49.03M) | (26.37M) | (73.34M) | 30.79M | 82.76M | 99.15M | 26.62M | (1.86M) | (33.13M) | (107.59M) | (99.88M) | (74.24M) |
| Total Assets | 804.33M | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B | 479.45M | 339.79M | 265.30M | 282.08M | 307.34M | 117.88M |
| Total Debt | 290.00M | 683.35M | 596.24M | 584.27M | 581.90M | 450.68M | 168.20M | 149.27M | 97.34M | 96.23M | 23.10M | 321,000 |
| Cash & Equiv | 103.39M | 163.77M | 240.82M | 115.33M | 209.61M | 246.17M | 179.42M | 140.62M | 78.59M | 99.78M | 119.42M | 57.61M |
| Book Value | 340.47M | 360.18M | 362.50M | 441.17M | 410.49M | 476.53M | 217.79M | 112.26M | 113.56M | 142.34M | 250.82M | 97.88M |
| Return on Equity | -0.40 | -0.47 | -0.57 | -0.21 | -0.14 | 0.04 | -0.03 | -0.57 | -0.54 | -0.93 | -0.44 | -0.82 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.58M | 174.06M | 174.35M | 167.20M | 158.81M | 154.99M | 161.27M | 155.09M | 150.36M | 138.50M | 133.78M | 127.32M |
| Net Income | (15.66M) | (71.14M) | (24.50M) | (37.27M) | (40.14M) | (34.32M) | (65.92M) | (30.57M) | (33.38M) | (38.76M) | (47.08M) | (49.48M) |
| EPS | -0.13 | -0.62 | -0.22 | -0.33 | -0.36 | -0.31 | -0.61 | -0.28 | -0.31 | -0.36 | -0.44 | -0.46 |
| Free Cash Flow | 5.53M | (18.67M) | (22.90M) | 14.92M | (21.42M) | (46.28M) | (12.39M) | (307,000) | (13.17M) | (43.36M) | (21.38M) | (26.57M) |
| FCF / Share | 0.05 | -0.16 | -0.21 | 0.13 | -0.19 | -0.42 | -0.11 | -0.00 | -0.12 | -0.40 | -0.20 | -0.25 |
| Operating CF | 12.44M | (13.52M) | (18.00M) | 20.57M | (15.94M) | (35.66M) | (3.45M) | 10.38M | (1.72M) | (31.57M) | (14.56M) | (19.31M) |
| Total Assets | 795.19M | 787.93M | 804.33M | 1.36B | 1.25B | 1.25B | 1.24B | 1.22B | 1.21B | 1.12B | 1.15B | 1.15B |
| Total Debt | 233.42M | 234.94M | 290.00M | 797.94M | 700.25M | 696.73M | 683.35M | 675.63M | 675.20M | 595.26M | 596.24M | 590.04M |
| Cash & Equiv | 93.70M | 97.32M | 103.39M | 344.64M | 149.62M | 127.28M | 163.77M | 185.42M | 168.44M | 453.76M | 240.82M | 154.86M |
| Book Value | 338.09M | 330.72M | 340.47M | 341.33M | 349.44M | 361.96M | 360.18M | 360.78M | 361.75M | 359.36M | 362.50M | 393.70M |
| Return on Equity | -0.05 | -0.22 | -0.07 | -0.11 | -0.11 | -0.09 | -0.18 | -0.08 | -0.09 | -0.11 | -0.13 | -0.13 |
NVCR News
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
NovoCure: Why I'm Fading The Q2 Earnings Rally
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
NovoCure Q2 Earnings Call Highlights
Novocure Reports Second Quarter 2026 Financial Results
Novocure Reports Second Quarter 2026 Financial Results